Trial reportMolecular psychiatry2026
Rate and predictors of remission and recovery in first-episode psychosis: A 12-year follow-up of randomized-controlled trial on early intervention.
Trial report in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Remission and recovery are key treatment goals in psychotic disorders. This was a 12-year follow-up of a single-blind randomized-controlled trial (RCT) comparing 1-year extension of early intervention (EI) (3-year EI) with 1-year step-down standard care (SC) (2-year EI) in patients who had completed 2-year specialized EI service (EASY program) in Hong-Kong. We systematically examined rates and predictors of symptomatic remission (SR), functional recovery (FR), personal recovery (PR), clinical recovery (fulfilled sustained SR and FR) and full recovery (fulfilled clinical recovery and PR) at 12-year follow-up. A comprehensive array of assessments was conducted encompassing premorbid adjustment and schizoid-schizotypal personality-traits (PSST), onset profiles, symptom dimensions, psychosocial functioning and treatment characteristics. LASSO-penalized and multivariate logistic-regression analyses were performed to construct prediction models of various remission/recovery outcomes. Correlational analyses exploring associations of PR with symptom and functional variables were conducted. A total of 106 of 160 of the initial patient cohort completed 12-year follow-up assessment. Rates of SR, FR, PR, clinical recovery and full recovery were 74.5, 24.5, 50.5, 22.6 and 16%, respectively. PSST and baseline functioning represented important predictors of FR and clinical recovery, while Extended EI was retained in prediction models for SR and full recovery. FR constituted a rate-limiting factor for clinical recovery and full recovery attainment. PR was negatively associated with negative and depressive symptoms, and positively related to psychosocial functioning. Our findings of potential effect of extended EI on long-term outcomes, however, should be treated with caution due to attrition bias, and a sizeable proportion of patients were functionally-impaired.
Indexed as
Identifiers
41388146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.